Take­da adds a $790M dis­cov­ery deal to an on­go­ing R&D over­haul


Fo­cus­ing hard on over­haul­ing R&D, Take­da has moved from re­or­ga­niz­ing and down­siz­ing to ink­ing new col­lab­o­ra­tions with dis­cov­ery out­fits around the world.

To­day the glob­al Japan­ese com­pa­ny, which has been con­cen­trat­ing much of its re­search pow­er in the Cam­bridge, MA area, has aligned it­self with Crescen­do Bi­o­log­ics in Cam­bridge, UK. Take­da is com­mit­ting $36 mil­lion in near-term cash and a fur­ther $754 mil­lion in mile­stones to jump on board the biotech’s Hum­a­body plat­form, which re­lies on its unique trans­genic mouse mod­el to find com­pact an­ti­bod­ies that have the po­ten­tial to make tempt­ing drug pro­grams.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.